Bifidobacterium bifidum PRL2010 alleviates intestinal ischemia/reperfusion injury

PLoS One. 2018 Aug 30;13(8):e0202670. doi: 10.1371/journal.pone.0202670. eCollection 2018.

Abstract

Mesenteric ischemia/reperfusion is a clinical emergency with high morbidity and mortality due to the transient reduction of blood supply to the bowel. In recent years, the critical contribution of gut microbiome to human health and proper gastrointestinal functions has gradually emerged. In the current study, we investigated the protective effects of five days supplementation with Bifidobacterium bifidum PRL2010 in a murine model of gut ischemia/reperfusion. Our findings indicate that animals pretreated with B. bifidum PRL2010 showed lower neutrophil recruitment in the lungs, remarkably reduced bacterial translocation and decreased transcription levels of TNFalpha and IL-10 both in liver and kidneys, at the same time increasing those of IL-12 in kidneys. Inhibiting the adhesion of pathogenic bacteria and boosting host innate immunity responses are among the possible protective mechanisms enacted by the probiotic. These results demonstrate that short-period treatment with B. bifidum PRL2010 is a potential strategy to dampen remote organ injury due to mesenteric ischemia/reperfusion.

MeSH terms

  • Animals
  • Bifidobacterium bifidum / physiology*
  • Disease Models, Animal
  • Feces / microbiology
  • Female
  • Immunity, Innate
  • Interleukin-10 / metabolism
  • Intestines / microbiology*
  • Intestines / pathology
  • Kidney / metabolism
  • Liver / metabolism
  • Lung / immunology
  • Lung / pathology
  • Malondialdehyde / metabolism
  • Mice
  • Neutrophils / cytology
  • Neutrophils / immunology
  • Probiotics / administration & dosage
  • Reperfusion Injury / immunology
  • Reperfusion Injury / pathology*
  • Reperfusion Injury / prevention & control
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Malondialdehyde

Grant support

We thank GenProbio srl for financial support of the Laboratory of Probiogenomics. The funder provided support in the form of salaries for L.M., M.M. and A.V. and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. DvS is a member of The APC Microbiome Institute funded by Science Foundation Ireland (SFI), through the Irish Government’s National Development Plan (Grant number SFI/12/RC/2273). Part of this research was conducted using the High Performance Computing (HPC) facility of the University of Parma.